Literature DB >> 18579530

Quinone reductase 2 is a catechol quinone reductase.

Yue Fu1, Leonid Buryanovskyy, Zhongtao Zhang.   

Abstract

The functions of quinone reductase 2 have eluded researchers for decades even though a genetic polymorphism is associated with various neurological disorders. Employing enzymatic studies using adrenochrome as a substrate, we show that quinone reductase 2 is specific for the reduction of adrenochrome, whereas quinone reductase 1 shows no activity. We also solved the crystal structure of quinone reductase 2 in complexes with dopamine and adrenochrome, two compounds that are structurally related to catecholamine quinones. Detailed structural analyses delineate the mechanism of quinone reductase 2 specificity toward catechol quinones in comparison with quinone reductase 1; a side-chain rotational difference between quinone reductase 1 and quinone reductase 2 of a single residue, phenylalanine 106, determines the specificity of enzymatic activities. These results infer functional differences between two homologous enzymes and indicate that quinone reductase 2 could play important roles in the regulation of catecholamine oxidation processes that may be involved in the etiology of Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579530      PMCID: PMC2527206          DOI: 10.1074/jbc.M801371200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

Review 1.  Benzene, NQO1, and genetic susceptibility to cancer.

Authors:  M T Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease.

Authors:  K Aoyama; K Matsubara; M Kondo; Y Murakawa; M Suno; K Yamashita; S Yamaguchi; S Kobayashi
Journal:  Neurosci Lett       Date:  2001-01-26       Impact factor: 3.046

3.  Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci.

Authors:  A Clairmont; H Sies; S Ramachandran; J T Lear; A G Smith; B Bowers; P W Jones; A A Fryer; R C Strange
Journal:  Carcinogenesis       Date:  1999-07       Impact factor: 4.944

4.  Crystal structure of human quinone reductase type 2, a metalloflavoprotein.

Authors:  C E Foster; M A Bianchet; P Talalay; Q Zhao; L M Amzel
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

5.  Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.

Authors:  R J Knox; T C Jenkins; S M Hobbs; S Chen; R G Melton; P J Burke
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

6.  Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease.

Authors:  D M Kuhn; R E Arthur; D M Thomas; L A Elferink
Journal:  J Neurochem       Date:  1999-09       Impact factor: 5.372

Review 7.  Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen.

Authors:  A T Dinkova-Kostova; P Talalay
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

Review 8.  Structures of mammalian cytosolic quinone reductases.

Authors:  C E Foster; M A Bianchet; P Talalay; M Faig; L M Amzel
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

Review 9.  Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2).

Authors:  S Chen; K Wu; R Knox
Journal:  Free Radic Biol Med       Date:  2000-08       Impact factor: 7.376

10.  Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release.

Authors:  M Faig; M A Bianchet; P Talalay; S Chen; S Winski; D Ross; L M Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  18 in total

1.  The antidote effect of quinone oxidoreductase 2 inhibitor against paraquat-induced toxicity in vitro and in vivo.

Authors:  Elzbieta Janda; Maddalena Parafati; Serafina Aprigliano; Cristina Carresi; Valeria Visalli; Iolanda Sacco; Domenica Ventrice; Tiziana Mega; Nuria Vadalá; Stefano Rinaldi; Vincenzo Musolino; Ernesto Palma; Santo Gratteri; Domenicantonio Rotiroti; Vincenzo Mollace
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.

Authors:  Arup Maiti; P V Narasimha Reddy; Megan Sturdy; Laura Marler; Scott D Pegan; Andrew D Mesecar; John M Pezzuto; Mark Cushman
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

3.  Bioactive compounds from the fern Lepisorus contortus.

Authors:  Jian-Hong Yang; Tamara P Kondratyuk; Katherine C Jermihov; Laura E Marler; Xi Qiu; Yongsoo Choi; Hongmei Cao; Rui Yu; Megan Sturdy; Rong Huang; Ying Liu; Li-Qin Wang; Andrew D Mesecar; Richard B van Breemen; John M Pezzuto; Harry H S Fong; Ye-Gao Chen; Hong-Jie Zhang
Journal:  J Nat Prod       Date:  2011-01-24       Impact factor: 4.050

4.  Crystallization via tubing microfluidics permits both in situ and ex situ X-ray diffraction.

Authors:  Charline J J Gerard; Gilles Ferry; Laurent M Vuillard; Jean A Boutin; Leonard M G Chavas; Tiphaine Huet; Nathalie Ferte; Romain Grossier; Nadine Candoni; Stéphane Veesler
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2017-10-02       Impact factor: 1.056

5.  Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2.

Authors:  P V Narasimha Reddy; Katherine C Jensen; Andrew D Mesecar; Phillip E Fanwick; Mark Cushman
Journal:  J Med Chem       Date:  2011-12-29       Impact factor: 7.446

6.  Interplay of flavin's redox states and protein dynamics: an insight from QM/MM simulations of dihydronicotinamide riboside quinone oxidoreductase 2.

Authors:  Robyn M Mueller; Michael A North; Chee Yang; Sanchita Hati; Sudeep Bhattacharyya
Journal:  J Phys Chem B       Date:  2011-03-16       Impact factor: 2.991

7.  Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.

Authors:  Chao Yan; Marine Dufour; David Siegel; Philip Reigan; Joe Gomez; Biehuoy Shieh; Christopher J Moody; David Ross
Journal:  Biochemistry       Date:  2011-07-19       Impact factor: 3.162

Review 8.  Defective autophagy in Parkinson's disease: role of oxidative stress.

Authors:  Elzbieta Janda; Ciro Isidoro; Cristina Carresi; Vincenzo Mollace
Journal:  Mol Neurobiol       Date:  2012-08-17       Impact factor: 5.590

9.  Potential chemopreventive agents based on the structure of the lead compound 2-bromo-1-hydroxyphenazine, isolated from Streptomyces species, strain CNS284.

Authors:  Martin Conda-Sheridan; Laura Marler; Eun-Jung Park; Tamara P Kondratyuk; Katherine Jermihov; Andrew D Mesecar; John M Pezzuto; Ratnakar N Asolkar; William Fenical; Mark Cushman
Journal:  J Med Chem       Date:  2010-11-24       Impact factor: 7.446

10.  Cyclic Changes in Active Site Polarization and Dynamics Drive the 'Ping-pong' Kinetics in NRH:Quinone Oxidoreductase 2: An Insight from QM/MM Simulations.

Authors:  Clorice R Reinhardt; Quin H Hu; Caitlin G Bresnahan; Sanchita Hati; Sudeep Bhattacharyya
Journal:  ACS Catal       Date:  2018-11-14       Impact factor: 13.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.